Download Hydroquinone Basics

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Hydroquinone
Basics
Images
Description
Formulation
Details
Eldoquin® [Valeant Pharmaceuticals ] (2%)
Formulation
Details
Eldoquin Forte® [Valeant Pharmaceuticals ] (4%)
Formulation
Details
Eldopaque Forte® [Valeant Pharmaceuticals ] (4%)
Formulation
Details
Eldopaque® [Valeant Pharmaceuticals ] (2%)
Formulation
Details
Esoterica® Nighttime [Medicis Dermatologics Inc] (2%)
Formulation
Details
Esoterica® Daytime [Medicis Dermatologics Inc] (2%)
Formulation
Details
Esoterica® Daytime [Medicis Dermatologics Inc] (2%)
Formulation
Details
Melanex® [Neutrogena Corp] (3%)
Formulation
Details
[Perrigo Pharmaceuticals] (5%)
Formulation
Details
[Perrigo Pharmaceuticals] (4%)
Formulation
Details
[Perrigo Pharmaceuticals] (4%)
Formulation
Details
[Perrigo Pharmaceuticals] (4%)
Formulation
Details
[Perrigo Pharmaceuticals] (4%)
Formulation
Details
[Perrigo Pharmaceuticals] (4%)
Formulation
Details
Lustra® [Taro Pharmaceuticals USA Inc] (4%)
Formulation
Details
Lustra-AF® [Taro Pharmaceuticals USA Inc] (4%)
Formulation
Details
Lustra-Ultra™ [Taro Pharmaceuticals USA Inc] (4%)
Images
Description
Formulation
Details
Melquin HP® [Stratus Pharmaceuticals Inc] (4%)
Formulation
Details
Melpaque HP® [Stratus Pharmaceuticals Inc] (4%)
Formulation
Details
Nuquin HP® [Stratus Pharmaceuticals Inc] (4%)
Formulation
Details
Melquin-3® [Stratus Pharmaceuticals Inc] (3%)
Formulation
Details
Nuquin HP® [Stratus Pharmaceuticals Inc] (4%)
Formulation
Details
Alphaquin HP® [Stratus Pharmaceuticals Inc] (4%)
Formulation
Details
EpiQuin® Micro [SkinMedica Inc] (4%)
Formulation
Details
Aclaro® [JSJ Pharmaceuticals] (4%)
Formulation
Details
Aclaro PD® [JSJ Pharmaceuticals] (4%)
U.S. Brand Names
Aclaro; Aclaro PD; Alphaquin HP; Eldopaque Forte; Eldopaque [OTC]; Eldoquin Forte; Eldoquin [OTC];
EpiQuin Micro; EpiQuin Micro/Pump [DSC]; Esoterica Daytime [OTC]; Esoterica Facial [OTC]; Esoterica Fade
Nighttime [OTC]; Esoterica Sensitive Skin [OTC]; Exuviance Lightening Complex [OTC]; Hydroquinone Time
Release; Lustra; Lustra-AF; Lustra-Ultra; Melpaque HP; Melquin 3; Melquin HP; NAVA-SC; NeoCeuticals
Post-Acne Fade [OTC]; NeoStrata HQ Skin Lightening [OTC]; Nuquin HP; Remergent HQ; Skin Bleaching;
Skin Bleaching-Sunscreen; TL Hydroquinone
Canadian Brand Names
Eldopaque®; Eldoquin®; Glyquin® XM; Lustra®; NeoStrata® HQ; Solaquin Forte®; Solaquin®;
Ultraquin™
Medication Safety Issues
Sound-alike/look-alike issues:
Eldopaque® may be confused with Eldoquin®
Eldopaque Forte® may be confused with Eldoquin Forte®
Generic Available (U.S.)
May be product dependent
Therapeutic Category
Depigmenting Agent
Related Terms
Hydroquinol; Quinol
Clinical Pharmacology
Mechanism of Action
Produces reversible depigmentation of the skin by suppression of melanocyte metabolic processes, in
particular the inhibition of the enzymatic oxidation of tyrosine to DOPA (3,4-dihydroxyphenylalanine); sun
exposure reverses this effect and will cause repigmentation.
Pharmacokinetics (Adult data unless noted)
Onset and duration of depigmentation produced by hydroquinone varies among individuals
Indications & Usage
Use
Gradual bleaching of hyperpigmented skin conditions
Contraindications
Hypersensitivity to hydroquinone or any component of the formulation; sunburn, depilatory usage
Warnings/Precautions
Other warnings/precautions:
• Appropriate use: Limit application to area no larger than face and neck or hands and arms.
Pregnancy & Lactation
Pregnancy Risk Factor
C
Pregnancy Implications
Animal reproduction studies have not been conducted with topical administration; the amount of systemic
absorption is unknown.
Lactation
Excretion in breast milk unknown/use caution
Adverse Reactions
Frequency not defined.
Dermatologic: Dermatitis, dryness, erythema, stinging, inflammatory reaction, sensitization
Local: Irritation
Interactions
Drug Interactions: Metabolism/Transport Effects
None known.
Drug Interactions
There are no known significant interactions.
Dosing
Dosing: Adults
Bleaching: Topical: Apply a thin layer and rub in twice daily.
Dosing: Elderly
Refer to adult dosing.
Dosing: Pediatric
Refer to adult dosing.
Available Products
Excipient information presented when available (limited, particularly for generics); consult specific product
labeling. [DSC] = Discontinued product
Cream, External:
Alphaquin HP: 4% (28.4 g, 56.7 g)
Eldopaque: 2% (28.35 g)
Eldopaque Forte: 4% (28.35 g)
Eldoquin: 2% (28.35 g)
Eldoquin Forte: 4% (28.35 g) [contains sodium metabisulfite]
EpiQuin Micro: 4% (30 g) [contains benzyl alcohol, methylparaben, sodium metabisulfite, trolamine
(triethanolamine), vitamin a, vitamin e]
EpiQuin Micro/Pump: 4% (40 g [DSC]) [contains benzyl alcohol, cetyl alcohol, edetate disodium,
methylparaben, sodium metabisulfite, trolamine (triethanolamine)]
Esoterica Daytime: 2% (70 g) [contains
propylparaben, sodium bisulfite]
disodium
edta,
methylparaben,
propylene
glycol,
Esoterica Daytime: 2% (70 g) [contains
propylparaben, sodium metabisulfite]
disodium
edta,
methylparaben,
propylene
glycol,
Esoterica Facial: 2% (85 g)
Esoterica Fade Nighttime: 2% (70 g) [contains disodium edta, methylparaben, propylene glycol,
propylparaben, sodium metabisulfite]
Esoterica Sensitive Skin: 1.5% (85 g)
Hydroquinone Time Release: 4% (30 g) [contains benzyl alcohol, cetyl alcohol, edetate disodium,
sodium metabisulfite, trolamine (triethanolamine)]
Lustra: 4% (56.8 g) [contains sodium metabisulfite]
Lustra-AF: 4% (56.8 g) [contains sodium metabisulfite, trolamine (triethanolamine)]
Lustra-Ultra: 4% (28.4 g, 56.8 g) [contains methylparaben, octyl methoxycinnamate (octinoxate),
propylparaben, sodium metabisulfite, vitamin a]
Melpaque HP: 4% (28.4 g)
Melquin HP: 4% (28.4 g)
NAVA-SC: 4% (28.4 g) [contains propylene glycol, sodium metabisulfite]
Nuquin HP: 4% (28.4 g, 56.7 g) [contains propylene glycol, sodium metabisulfite]
Remergent HQ: 4% (30 mL) [contains sodium metabisulfite]
Skin Bleaching: 4% (28.35 g)
Skin Bleaching-Sunscreen: 4% (28.35 g) [contains cetostearyl alcohol, glycerin, isopropyl palmitate,
propylene glycol, sodium lauryl sulfate, sodium metabisulfite, sorbic acid, water, purified]
TL Hydroquinone: 4% (30 g) [contains benzyl alcohol, cetearyl alcohol, cetyl alcohol, edetate
disodium, methylparaben, sodium metabisulfite, trolamine (triethanolamine)]
Generic: 4% (28.35 g)
Emulsion, External:
Aclaro: 4% (48.2 g) [contains benzyl alcohol, sodium metabisulfite]
Aclaro PD: 4% (42.5 g)
Gel, External:
Exuviance Lightening Complex: 2% (30 g) [contains denatured alcohol, propylene glycol, sodium
bisulfite, sodium sulfite, tartrazine (fd&c yellow #5)]
NeoCeuticals Post-Acne Fade: 2% (30 g) [contains denatured alcohol, propylene glycol, sodium
bisulfite, sodium sulfite, tartrazine (fd&c yellow #5)]
NeoStrata HQ Skin Lightening: 2% (30 g) [fragrance free, oil free; contains propylene glycol, sodium
bisulfite, sodium sulfite]
Nuquin HP: 4% (28.4 g)
Solution, External:
Melquin 3: 3% (29.57 mL)
Administration
Administration, Topical
For external use only; avoid contact with eyes
Monitoring
Breast-Feeding Considerations
It is not known if hydroquinone is excreted in breast milk. The manufacturer recommends that caution be
exercised when administering hydroquinone to nursing women
Patient Education
Discuss specific use of drug and side effects with patient as it relates to treatment. Patient may experience
short-term pain, xeroderma, or skin irritation. Have patient report immediately to prescriber rash. Educate
patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue
skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all
side effects. Patient should consult prescriber for additional questions.
View the Patient Handout: English | Spanish
AccessPharmacy © 1978-Present McGraw-Hill and/or its respective owners.
Copyright © McGraw-Hill Global Education Holdings, LLC. All rights reserved.
Privacy Notice. Any use is subject to the Terms of Use and Notice.
Your IP address is 187.237.17.2
Related documents